Clinical Trials Browser

Unknown × Carcinoma, Non-Small-Cell Lung × sintilimab × Clear all

NCT06267144 2024-02-20

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04612673 2020-11-03

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04252365 2020-02-05

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04213170 2019-12-30

Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04124731 2019-10-11

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Phase 2 Unknown

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04106180 2019-09-26

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03874000 2019-03-19

SMART

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms